knowledge -WSS

knowledge

author：explore 2025-09-30 01:01:53 - browse：65

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Change Healthcare: What is it, why does its cyberattack matter?

WSS

Ozempic has benefits for kidney disease as well as diabetes

Can U.S. cancer drug shortages be fixed?

Immune cells and nerve overgrowth may explain recurring UTI pain

Wegovy improves function in certain heart failure patients

He's 19 months old and has one of the world’s rarest diseases

Readout Newsletter: BridgeBio, Akero, and human embryo models

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Streamlined flu vaccines recommended by FDA advisory panel

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Harvard's David Sinclair gets blowback over aging

Drug repurposing or repositioning? The language matters

Families look for replacement for GSK asthma drug Flovent

In Memoriam: Notable people who died in 2023

$1 billion proposal to grow Boston, Massachusetts biotech

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

entertainment

How the drug

Immune cells and nerve overgrowth may explain recurring UTI pain

Lack of health data on LGBTQ+ people has serious consequences

Kellogg’s is going to war over Mexico’s nutrition label rules

The untold story of TV’s first prescription drug ad

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

focus

focus

hotspot

explore